A Pakistani Type 2 diabetic patient shares a journey through three doctors, four medicines, and three years of stubborn weight plateau — a story that mirrors millions of Pakistanis managing diabetes without proper guidance.
By Imran Malik | Health & Pharma Desk | MediaBites.com.pk
An HbA1c reading of 6.7. A weight stuck at 108.5 kg for three consecutive years. Three different doctors. Four medication changes. And one persistent question millions of Pakistani diabetic patients carry silently every day: Am I taking the right medicine?
This is not one patient’s story. This is Pakistan’s story.
Pakistan’s Diabetes Crisis — The Numbers
Pakistan has over 36 million diagnosed diabetic patients, the world’s highest diabetes prevalence rate at 30.8%, nearly three times the global average. By 2050, that figure may reach 70.2 million.
Type 1 Diabetes is an autoimmune condition destroying insulin-producing cells, typically diagnosed in childhood, requiring lifelong insulin. It accounts for 5 to 10% of cases.
Type 2 Diabetes represents over 90% of Pakistan’s diabetic population. The body either fails to produce enough insulin or cannot use it effectively. Diet, weight, inactivity, and genetics all contribute. This is where the vast majority of Pakistani patients fall.
The Medication Journey — Familiar to Millions
Stage 1: Metformin / Glucophage
The standard first prescription for Type 2 diabetes in Pakistan is Metformin, most commonly under the brand name Glucophage by Merck. It reduces liver glucose production and improves insulin sensitivity. Other available brands include Metforal, Diaformin, Metmin, Gluformin, and Formet, as well as generics. Broad choice exists but creates confusion about which brand to trust.
Stage 2: Sitamet 50/500
After months on Metformin, many patients move to combination therapy. Sitamet 50/500, manufactured by CCL Pharmaceuticals, combines Sitagliptin (50mg) and Metformin (500mg) taken twice daily after meals. Sitagliptin is a DPP-4 inhibitor that increases the levels of natural hormones that control blood sugar after meals. Many endocrinologists consider this dual mechanism more effective than Metformin alone for moderate HbA1c levels. A multivitamin such as Centrum is often added at this stage.
Stage 3: Sitamet XR and Rosuvastatin
The extended-release formulation Sitamet XR 50/500 releases medication gradually, reducing gastrointestinal side effects while maintaining consistent blood sugar control. At this stage, Rosuvastatin, sold in Pakistan as Rovista, Crestor, and Rosustat, is often added at 5mg daily. This statin lowers LDL cholesterol and reduces cardiovascular risk, reflecting the clinically documented fact that diabetic patients are two to four times more likely to develop heart disease.
The Sitagliptin-Metformin Brand Question
Patients prescribed Jentim Met or Jentamet by family doctors may not know that multiple brands carry the identical salt combination. Available brands include Janumet by MSD, Sitamet by CCL, Jentamet, Xelevia Met, Tesavel Met, and various generics. Active ingredients may be identical, but brand loyalty and clinic pharmacy availability often drive prescriptions more than clinical evidence.
Why Has the Weight Not Moved in Three Years?
This is the most common and least discussed frustration among Pakistani Type 2 diabetic patients.
A weight of 108.5 kg, unchanged over three years despite diabetes treatment, is medically explicable and deeply connected to insulin resistance itself. When cells resist insulin’s signal, the body compensates by producing more. Elevated insulin levels actively promote fat storage, particularly abdominal fat, and inhibit the body’s ability to break down stored fat for energy.
The result is a physiological trap. Excess weight worsens insulin resistance. Insulin resistance makes weight loss harder. Standard medications including Metformin and Sitagliptin, are largely weight-neutral. They control HbA1c. They do not reliably produce meaningful weight loss.
A three-year weight plateau at 108.5 kg in a Type 2 diabetic with an HbA1c of 6.7 strongly suggests that the current regimen may need review, not only for blood sugar targets but also for overall metabolic and weight management outcomes.
READ MORE: Pakistan faces a Diabetes explosion while local Pharma Companies race to produce affordable Ozempic and Mounjaro alternatives
Newer Options Most Pakistani Patients Do Not Know About
GLP-1 receptor agonists, including Semaglutide (Ozempic, Wegovy) and Tirzepatide (Mounjaro), simultaneously improve blood sugar control and produce substantial weight loss of 10 to 20% of body weight over 12 to 18 months. As covered in a previous MediaBites article, these remain accessible only to upper-income urban patients in Pakistan. Monthly Ozempic costs PKR 60,000 to 110,000. Generic manufacturing by Getz Pharma, Ferozsons, BF Biosciences, and GD Searle is underway and may significantly reduce costs.
The Doctor-Clinic Pharmacy Problem
Every time a new doctor is consulted, the prescription changes to medicines coincidentally available at that clinic’s attached pharmacy. This raises legitimate questions about whether prescriptions reflect clinical evidence or commercial relationships. Remaining loyal to a medication that works is not wrong. But patients deserve transparency about why a specific brand is being prescribed.
Are Supplements Actually Necessary?
Metformin is known to reduce Vitamin B12 absorption over time, making B12 supplementation clinically relevant for long-term users. Vitamin D deficiency, highly prevalent in Pakistan, worsens insulin resistance. Magnesium deficiency also affects blood sugar regulation.
However, taking a broad-spectrum multivitamin without knowing which nutrients are deficient is not optimal. The better approach is to ask your doctor to specifically check Vitamin B12, Vitamin D, and Magnesium levels, then supplement based on the actual results.
Why can’t Pakistani Pharma Deliver Medicines to patients’ doorsteps?
Pakistan has 36 million diabetic patients requiring consistent monthly medication. Inconsistent access is one of the primary drivers of poor diabetes outcomes. Some pharmacies offer 5-9% discounts without home delivery. Major companies, including CCL, Getz Pharma, and Ferozsons, have the distribution infrastructure to establish direct-to-patient monthly subscription models with home delivery and meaningful discounts. The commercial case is straightforward. Thirty-six million monthly subscribers are one of Pakistan’s largest captive consumer markets. The technology exists. The patient base exists. The will is what is missing.
A Call to Pakistan’s Medical and Pharma Community
To every endocrinologist, physician, nutritionist, pharmacist, and pharmaceutical professional reading this: your knowledge in the comments could change the treatment outcomes of thousands of Pakistani patients navigating this journey with incomplete information and inconsistent guidance.
The conversation starts here.
This article is for health awareness only and does not constitute medical advice. Consult a qualified physician or endocrinologist before making any changes to your treatment plan.
